Volume 3 (2016): Issue 1

The SIPPET study: what impact will it have on haemophilia care?

Open Access | | Creative Commons Attribution NonCommercial NoDerivatives
Cedric Hermans MD, PhDFRCP (Lon, Edin)

Abstract

Abstract

The long-awaited results of the SIPPET (Survey of Inhibitors in Plasma-Products Exposed Toddlers) study were recently presented during a plenary session at the American Society of Hematology (ASH) conference in December 2015.

Article

View Full Article

References

  • 1. Peyvandi F, Mannucci PM, Garagiola I, et al. Source of Factor VIII Replacement (plasmatic or recombinant) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study. Presented at American Society of Hematology. December, 2015. https://ash.confex.com/ash/2015/webprogram/Paper82866.html
  • 2. Gouw SC, van den Berg HM, Fischer K, et al; PedNet and Research of Determinants of INhibitor development (RODIN) Study Group. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood 2013; 121(20): 4046-55. doi: 10.1182/blood-2012-09-457036.
  • 3. Andrea Messori A. The SIPPET trial and the economic consequences of developing high-titre inhibitors in hemophilia A. BMJ 2015; 350:h870

PDF Download

Download PDF

Open in full-page viewer

Authors